For the quarter ended September 2025, Guardant Health (GH) reported revenue of $265.2 million, up 38.5% over the same period last year. EPS came in at -$0.39, compared to -$0.45 in the year-ago quarter.
The reported revenue represents a surprise of +13.05% over the Zacks Consensus Estimate of $234.58 million. With the consensus EPS estimate being -$0.48, the EPS surprise was +18.75%.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.
Here is how Guardant Health performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Total tests performed (oncology tests): 74,000 versus 66,824 estimated by three analysts on average.
- Revenue- Oncology: $184.4 million versus the four-analyst average estimate of $164.62 million.
- Revenue- Biopharma and data: $54.73 million compared to the $48.38 million average estimate based on four analysts.
- Revenue- Screening: $24.11 million versus $16.31 million estimated by four analysts on average.
- Revenue- Licensing and other: $1.95 million versus $2.35 million estimated by three analysts on average.
View all Key Company Metrics for Guardant Health here>>>
Shares of Guardant Health have returned +11.4% over the past month versus the Zacks S&P 500 composite's +3.8% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Guardant Health, Inc. (GH): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
